Author/Authors :
Farhadi Mohammad نويسنده , Izadi Farzad نويسنده MD., Associate Professor , Khorram Khorshid Hamid Reza نويسنده Genetic Research Center,University of Social Welfare and Rehabilitation Science,Tehran,Iran , Bahri Maryam نويسنده ENT-Head and Neck Surgery Research Center and Department,
Rasool Akram Hospital, Iran University of Medical Sciences, Tehran,
IR Iran , Derakhshandeh Vitta نويسنده ENT-Head and Neck Surgery Research Center and Department,
Rasool Akram Hospital, Iran University of Medical Sciences, Tehran,
IR Iran , Tavakoli Mohammad Moein نويسنده ENT-Head and Neck Surgery Research Center and Department,
Rasool Akram Hospital, Iran University of Medical Sciences, Tehran,
IR Iran , Madani Hessamodin نويسنده ENT-Head and Neck Surgery Research Center and Department,
Rasool Akram Hospital, Iran University of Medical Sciences, Tehran,
IR Iran , Shahrivar Roya نويسنده ENT-Head and Neck Surgery Research Center and Department,
Rasool Akram Hospital, Iran University of Medical Sciences, Tehran,
IR Iran , Ahmadi Aslan نويسنده ENT-Head and Neck Surgery Research Center and Department,
Rasool Akram Hospital, Iran University of Medical Sciences, Tehran,
IR Iran
Abstract :
Background Contovir is a mixture of herbal extracts (Tanacetum
vulgare, Rossa canina, Urtica dioica) that is supplemented with
selenium. Objectives This study aimed to add Contovir to the classic
treatment of recurrent respiratory papillomatosis (RRP) in order to
decrease the severity and extent of the disease, elongate the surgical
intervals and improve the sense of patient well-being. Furthermore, we
had to adjust the prescribed drug dosage, since there were no previous
findings available. Patients and Methods This is a case study of RRP
patients treated with Contovir as an adjuvant to the classic treatment,
from March 2011 to February 2013, at an academic tertiary hospital
(Rasoul-e-Akram hospital). All patients underwent surgical removal of
papilloma and then were prescribed Contovir. Disease severity was
quantified based on Derkay’s staging system. Results Eight patients were
enrolled in this study. The extent and severity of the disease improved
in six cases. One had no response, and the severity of disease increased
in one patient. Patients with supraglottic lesions had better responses
to Contovir adjuvant therapy. No immediate or long-term side effects
were reported. Conclusions Although Contovir has been found to be an
advantageous adjuvant for RRP treatment, further studies are called for
to verify these findings.
